Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis


Efficacy results from the Phase 2 study in patients with moderate to severe atopic dermatitis showed there was no benefit from OC459 compared to placebo. Overall OC459 was generally well tolerated with a similar safety profile to previous studies.

Tim Edwards, Executive Chairman of Atopix commented: “Whilst we were disappointed not to have seen positive efficacy results in this study the data have served to provide us with deeper insight into the role of CRTH2 antagonists and we now believe they have no role in the treatment of atopic dermatitis. We still believe, however, that the CRTH2 pathway is active in eosinophilic asthma and so, encouraged by further good safety results, we will now focus our efforts into developing OC459 for the treatment of TH2-mediated eosinophilic asthma.”

The Phase 2 trial was a randomised, double blind, placebo controlled study designed to determine the effectiveness of OC459 in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (clinical.trials.gov identifier: NCT02002208).

Following completion of the full study analysis, further details will be made available on public databases.

For more information please contact:

Atopix Therapeutics Ltd
Tim Edwards, Executive Chairman
+44 (0) 1235 841563
atopix@atopixtherapeutics.co.uk

Consilium Strategic Communications
Amber Fennell, Chris Gardner, Lindsey Neville
Tel: +44 (0) 203 709 5700
Email: atopix@consilium-comms.com
About Atopix Therapeutics Ltd
Atopix Therapeutics Limited is a clinical-stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. Atopix has a pipeline of once-daily, oral small molecule CRTH2 antagonists for Th2-mediated disorders. Its lead product, OC459, is in three proof-of-concept clinical studies and its next-generation CRTH2 antagonist, ATX2417, is being assessed in a Phase 1 trial. Atopix is based in Oxford, UK and is backed by highly experienced investors including SR One, Wellington Partners, SV Life Sciences and MPM Capital.

For more information, please visit http://www.atopixtherapeutics.com.

About Th2-mediated disease
The Th2 mechanism is central to a range of diseases including eosinophilic asthma. Therapies targeting Th2 have the potential to offer significant advances in treatments for patients with eosinophilic disease. Clinical validation is building with studies of therapies counteracting Th2 responses under development at major pharmaceutical companies and showing positive results in clinical trials. Atopix is developing highly specific, highly potent oral Th2 drug candidates that address CRTH2 – a cell surface receptor pivotal to the Th2 mechanism – and which possess excellent drug like characteristics.

About OC459
OC459 is Atopix’s lead development candidate - an orally active CRTH2 antagonist. OC459 was the first to demonstrate the clinical utility of CRTH2 antagonists and has been shown to be effective in the treatment of eosinophilic asthma and allergic rhinitis. It is effective when dosed once a day and provides marked improvements in patients with a Th2 dominant form of the disease who typically experience more severe symptoms and are prone to exacerbations. OC459 has demonstrated an excellent safety profile in more than 800 patients. OC459 is now being studied in three clinical studies with highly-targeted patient populations in severe eosinophilic asthma.